From Immunology and Allergy Clinics:
Immunoglobulin replacement therapy has been standard treatment in patients with primary immunodeficiency diseases for the past 3 decades. Until recently, it was mostly IVIG, with SCIG taking a large share nowadays.
The goal of therapy is to reduce serious bacterial infections in individuals with antibody function defects.
Approximately one-third of patients receiving intravenous immunoglobulin (IVIG) treatment experience adverse reactions. Recent advances in manufacturing processes have resulted in products that are safer and better tolerated.
Self-infusion by the subcutaneous route (SCIG) has become popular and resulted in better quality of life.
Immunoglobulin Replacement Therapy for Primary Immunodeficiency - Immunology and Allergy Clinics http://buff.ly/1PTv1hd